Snyder Capital Management L P Has $32.85 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Snyder Capital Management L P boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 15.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 177,927 shares of the medical research company's stock after purchasing an additional 24,086 shares during the period. Snyder Capital Management L P owned about 0.35% of Charles River Laboratories International worth $32,845,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of CRL. Versant Capital Management Inc raised its holdings in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after acquiring an additional 150 shares during the period. Pinnacle Bancorp Inc. raised its holdings in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares during the period. GeoWealth Management LLC raised its holdings in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after acquiring an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new position in Charles River Laboratories International in the 4th quarter valued at about $48,000. Finally, Tortoise Investment Management LLC raised its holdings in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after acquiring an additional 115 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRL has been the topic of several research analyst reports. Robert W. Baird lowered their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Morgan Stanley lowered their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. UBS Group reaffirmed a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded up $0.50 during trading hours on Monday, hitting $115.16. 1,372,628 shares of the stock were exchanged, compared to its average volume of 923,898. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The company has a market cap of $5.66 billion, a PE ratio of 767.73, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company's fifty day simple moving average is $145.74 and its two-hundred day simple moving average is $170.44. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the business posted $2.46 earnings per share. The company's quarterly revenue was down 1.1% on a year-over-year basis. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In related news, CEO James C. Foster acquired 6,075 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).